Catalysts
INSM Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
INSMInsmed Incorporated
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum61
- Value55
- Quality58
- Risk resilience49
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 61/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 26.55%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | — | -$0.38 | -$0.46 | -20.2% | $500.36M | $524.43M |
| Aug 6, 2026 | — | -$0.67 | -$0.06 | +91.1% | $395.5M | $425.49M |
| May 7, 2026 | — | -$0.96 | -$0.76 | +21.1% | $300.81M | $305.96M |
| Feb 19, 2026 | — | -$1.07 | -$1.54 | -43.9% | $231.25M | $263.84M |
| Oct 30, 2025 | — | -$1.33 | -$1.75 | -31.6% | $115.45M | $142.34M |
| Aug 7, 2025 | — | -$1.30 | -$1.70 | -30.8% | $104.13M | $107.42M |
| May 8, 2025 | — | -$1.34 | -$1.42 | -6.0% | $91.47M | $92.82M |
| Feb 20, 2025 | — | -$1.17 | -$1.32 | -12.8% | $102.08M | $104.44M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?
Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision...
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]
Related Links
INSM Catalysts FAQ
What are the next catalysts for INSM stock?
INSM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move INSM stock?
Upcoming events that could move INSM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could INSM's next earnings report affect the stock?
INSM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive INSM stock higher?
INSM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt INSM stock?
INSM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.